Enveric Biosciences Inc (ENVB) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ENVB Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Enveric Biosciences Inc adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent8.30
Cash & Short-term Investments8.00
Prepaid Expense And Other Assets Current0.00
Total Current Assets8.79
Equipment/Property/Plant Net0.08
Deferred Costs, Noncurrent AS0.07
Other Assets, Noncurrent0.50
Total Assets8.94
Liabilities
Accounts Payable, Current AC0.68
Accrued Liabilities, Current AC0.15
Other Liabilities, Current0.03
Total Current Liabilities0.86
Total Long-term Debt0.00
Total Liabilities0.86
Stockholders' Equity
Common Stock Value0.04
Additional Paid In Capital Common Stock128.15
Retained Earnings / Accumulated Deficit-119.51
Accumulated Other Comprehensive Income-0.59
Other Equity-0.59
Common Stockholder's Equity8.08
Total Stockholder's Equity8.08
Liabilities & Stockholder's Equity8.94
4 historic quarters locked

Sign in to unlock the full Enveric Biosciences Inc balance sheet history.

About Enveric Biosciences Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 14, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001493152-26-038418

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.